CXD 201
Alternative Names: CXD201Latest Information Update: 11 Jan 2023
At a glance
- Originator Oxford University Innovation
- Developer IngenOx Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 05 Jan 2023 Argonaut Therapeutics has merged with Celleron Therapeutics to form IngenOx Therapeutics
- 28 Sep 2021 No recent reports of development identified for phase-I development in Colorectal-cancer in United Kingdom (PO)
- 27 Aug 2019 Celleron Therapeutics plans a phase II trial for Colorectal cancer (Combination therapy) in European Union and China (Celleron Therapeutics pipeline, August 2019)